Tang Capital Management BEIGF Position
Exited4-Fund ConvergenceTang Capital Management exited their position in BeOne Medicines Ltd. (BEIGF) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
BEIGF is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Zanidatamab in 108 days (Jul 31, 2026), making the timing of Tang Capital's position particularly relevant.
Tang Capital Management BEIGF Position History
Frequently Asked Questions
Does Tang Capital Management own BEIGF?
No. Tang Capital Management exited their position in BeOne Medicines Ltd. (BEIGF) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own BEIGF?
4 specialist biotech hedge funds currently hold BEIGF, including Baker Bros. Advisors, Boxer Capital, Driehaus Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy BEIGF?
Tang Capital Management's position in BEIGF was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's BEIGF position increasing or decreasing?
Tang Capital Management completely exited their BEIGF position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BEIGFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →